Cargando…
Efficacy and safety of baricitinib in Japanese patients with autoinflammatory type I interferonopathies (NNS/CANDLE, SAVI, And AGS)
BACKGROUND: This study evaluated the efficacy and safety of baricitinib (Janus kinase-1/2 inhibitor), in adult and pediatric Japanese patients with Nakajo-Nishimura syndrome/chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (NNS/CANDLE), stimulator of interferon ge...
Autores principales: | Kanazawa, Nobuo, Ishii, Taeko, Takita, Yasushi, Nishikawa, Atsushi, Nishikomori, Ryuta |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10122451/ https://www.ncbi.nlm.nih.gov/pubmed/37087470 http://dx.doi.org/10.1186/s12969-023-00817-8 |
Ejemplares similares
-
JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies
por: Sanchez, Gina A. Montealegre, et al.
Publicado: (2018) -
Expression of interferon-regulated genes in juvenile dermatomyositis versus Mendelian autoinflammatory interferonopathies
por: Kim, Hanna, et al.
Publicado: (2020) -
Efficacy of Baricitinib in the Treatment of Chilblains Associated With Aicardi‐Goutières Syndrome, a Type I Interferonopathy
por: Meesilpavikkai, Kornvalee, et al.
Publicado: (2019) -
Pooled Safety Analysis of Baricitinib in Adult Participants with Atopic Dermatitis in the Japanese Subpopulation from Six Randomized Clinical Trials
por: Katoh, Norito, et al.
Publicado: (2022) -
Designation of Autoinflammatory Skin Manifestations With Specific Genetic Backgrounds
por: Kanazawa, Nobuo
Publicado: (2020)